Literature DB >> 9255577

Ethnic differences in cancer incidence: a marker for inherited susceptibility?

F D Gilliland1.   

Abstract

Cancer incidence varies markedly by ethnicity and geographic location. Ethnic variation in cancer occurrence has traditionally been ascribed to differences in social, cultural, economic, and physical environments. However, this interpretation of the epidemiologic evidence may need to be revised as a result of new biological evidence and theories of carcinogenesis. Carcinogenesis is now recognized to be a multistep process during which mutations or heritable changes in expression occur in genes involved in cellular growth control and genome stability. Inherited cancer susceptibility may be a stronger determinant of ethnic differences in cancer incidence than is currently appreciated. To examine the potential role of inherited susceptibility, the theoretical contribution of inherited susceptibility to ethnic differences in rates in considered using a simple probability model. Germline mutations in tumor suppressor genes BRCA1 and p53 are used to illustrate the magnitude of the ethnic differences for breast cancer that might arise from differences in inherited susceptibility. Our simple model suggests that ethnic differences in cancer occurrence can result from differences in genetic susceptibility. However, the magnitude of ethnic relative risk is likely to more strongly reflect differences in the distribution of susceptibility genotypes between groups than the magnitude of the disease risk associated with the genotypes. For many scenarios, the ethnic relative risk arising from differences in susceptibility may be bounded by the ratio of the proportion of susceptible individuals in each group.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255577      PMCID: PMC1470049          DOI: 10.1289/ehp.97105s4897

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  14 in total

1.  Hereditary cancer, oncogenes, and antioncogenes.

Authors:  A G Knudson
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

2.  Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.

Authors:  O Johannsson; E A Ostermeyer; S Håkansson; L S Friedman; U Johansson; G Sellberg; K Brøndum-Nielsen; V Sele; H Olsson; M C King; A Borg
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

3.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

Review 4.  Inherited breast and ovarian cancer.

Authors:  C I Szabo; M C King
Journal:  Hum Mol Genet       Date:  1995       Impact factor: 6.150

Review 5.  Antioncogenes and human cancer.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

6.  Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; D T Bishop; S A Narod; D E Goldgar
Journal:  Lancet       Date:  1994-03-19       Impact factor: 79.321

7.  Germline mutation of BRCA1 in Japanese breast cancer families.

Authors:  R Inoue; T Fukutomi; T Ushijima; Y Matsumoto; T Sugimura; M Nagao
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

Review 8.  The genetic predisposition to cancer.

Authors:  A G Knudson
Journal:  Birth Defects Orig Artic Ser       Date:  1989

Review 9.  Pharmacogenetics: detecting sensitive populations.

Authors:  P G Shields
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

Review 10.  The genetics of breast and ovarian cancer.

Authors:  D Ford; D F Easton
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

View more
  11 in total

1.  Y chromosome STR haplotypes and the genetic structure of U.S. populations of African, European, and Hispanic ancestry.

Authors:  Manfred Kayser; Silke Brauer; Hiltrud Schädlich; Mechthild Prinz; Mark A Batzer; Peter A Zimmerman; B A Boatin; Mark Stoneking
Journal:  Genome Res       Date:  2003-04       Impact factor: 9.043

2.  DNMT3B -579 G>T Promoter Polymorphism and the Risk of Gastric Cancer in the West of Iran.

Authors:  Kulsom Ahmadi; Azam Soleimani; Shiva Irani; Aliasghar Kiani; Kourosh Ghanadi; Zahra Noormohamadi; Foroozan Sakinejad
Journal:  J Gastrointest Cancer       Date:  2018-06

3.  Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient.

Authors:  Pithi Chanvorachote; Sudjit Luanpitpong; Preedakorn Chunhacha; Worrawat Promden; Virote Sriuranpong
Journal:  Oncol Lett       Date:  2012-05-10       Impact factor: 2.967

4.  Allele Frequencies of the Epidermal Growth Factor Receptors Polymorphism R521K in Colorectal Cancer Patients and Healthy Subjects Indicate a Risk-Reducing Effect of K521 in Syrian Population.

Authors:  Ola Haj Mustafa; Abdul Rezzak Hamzeh; Lina Ghabreau; Nizar Akil; Ala-Eddin Almoustafa; Amal Alachkar
Journal:  N Am J Med Sci       Date:  2013-03

5.  Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population.

Authors:  Gabriela Es Felix; Camila Abe-Sandes; Taísa Mb Machado-Lopes; Thaís F Bomfim; Rodrigo Santa Cruz Guindalini; Vanessa Catarine Sar Santos; Lorena Meyer; Polyanna C Oliveira; João Cláudio Neiva; Roberto Meyer; Maura Romeo; Maria Betânia Toralles; Ivana Nascimento; Kiyoko Abe-Sandes
Journal:  Hum Genome Var       Date:  2014-10-16

6.  Minority ethnicity patient satisfaction and experience: results of the National Cancer Patient Experience Survey in England.

Authors:  Richard J Pinder; Jamie Ferguson; Henrik Møller
Journal:  BMJ Open       Date:  2016-06-28       Impact factor: 2.692

7.  CYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case-control studies.

Authors:  Hongge Wang; Zhi Zhang; Sugui Han; Yujuan Lu; Fumin Feng; Juxiang Yuan
Journal:  BMC Cancer       Date:  2012-11-19       Impact factor: 4.430

8.  Extensive ethnogenomic diversity of endothelial nitric oxide synthase (eNOS) polymorphisms.

Authors:  Bolaji N Thomas; Tanya J Thakur; Li Yi; Aldiouma Guindo; Dapa A Diallo; Jurg Ott
Journal:  Gene Regul Syst Bio       Date:  2013-01-15

Review 9.  Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer.

Authors:  Wei Xu; Haifeng Zhang; Fa Wang; Honghui Wang
Journal:  Diagn Pathol       Date:  2013-06-17       Impact factor: 2.644

10.  Endothelin-1 but not Endothelial Nitric Oxide Synthase Gene Polymorphism is Associated with Sickle Cell Disease in Africa.

Authors:  Tanya J Thakur; Aldiouma Guindo; Londyn R Cullifer; Yi Li; Ikhide G Imumorin; Dapa A Diallo; Bolaji N Thomas
Journal:  Gene Regul Syst Bio       Date:  2014-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.